Familial cylindromatosis

Familial cylindromatosis is a condition involving multiple skin tumors that develop from structures associated with the skin (skin appendages), such as hair follicles and sweat glands. People with familial cylindromatosis typically develop large numbers of tumors called cylindromas. While previously thought to derive from sweat glands, cylindromas are now generally believed to begin in hair follicles.

Individuals with familial cylindromatosis occasionally develop other types of tumors, including growths called spiradenomas and trichoepitheliomas. Spiradenomas begin in sweat glands. Trichoepitheliomas arise from hair follicles. The tumors associated with familial cylindromatosis are generally noncancerous (benign), but occasionally they may become cancerous (malignant). Affected individuals are also at increased risk of developing tumors in tissues other than skin appendages, particularly benign or malignant tumors of the salivary glands.

People with familial cylindromatosis typically begin developing tumors in adolescence or early adulthood. The tumors are most often found in hairy regions of the body, with approximately 90 percent occurring on the head and neck. They grow larger and increase in number over time.

In severely affected individuals, multiple tumors on the scalp may combine into a large, turban-like growth. Large growths frequently develop open sores (ulcers) and are prone to infections. The tumors may also get in the way of the eyes, ears, nose, or mouth and affect vision, hearing, or other functions. The growths can be disfiguring and may contribute to depression or other psychological problems. For reasons that are unclear, females with familial cylindromatosis are often more severely affected than males.

Frequency

Familial cylindromatosis is a rare disorder; its prevalence is unknown.

Causes

Familial cylindromatosis is caused by mutations in the CYLD gene. This gene provides instructions for making a protein that helps regulate nuclear factor-kappa-B. Nuclear factor-kappa-B is a group of related proteins that help protect cells from self-destruction (apoptosis) in response to certain signals. In regulating the action of nuclear factor-kappa-B, the CYLD protein allows cells to respond properly to signals to self-destruct when appropriate, such as when the cells become abnormal. By this mechanism, the CYLD protein acts as a tumor suppressor, which means that it helps prevent cells from growing and dividing too fast or in an uncontrolled way.
People with familial cylindromatosis are born with a mutation in one of the two copies of the CYLD gene in each cell. This mutation prevents the cell from making functional CYLD protein from the altered copy of the gene. However, enough protein is usually produced from the other, normal copy of the gene to regulate cell growth effectively. For tumors to develop, a second mutation or deletion of genetic material involving the other copy of the CYLD gene must occur in certain cells during a person's lifetime.

When both copies of the CYLD gene are mutated in a particular cell, that cell cannot produce any functional CYLD protein. The loss of this protein allows the cell to grow and divide in an uncontrolled way to form a tumor. In people with familial cylindromatosis, a second CYLD mutation typically occurs in multiple cells over an affected person’s lifetime. The loss of CYLD protein in these cells leads to the growth of skin appendage tumors.

Some researchers consider familial cylindromatosis and two related conditions called multiple familial trichoepithelioma and Brooke-Spiegler syndrome, which are also caused by CYLD gene mutations, to be different forms of the same disorder. It is unclear why mutations in the CYLD gene cause different patterns of skin appendage tumors in each of these conditions, or why the tumors are generally confined to the skin in these disorders.

Inheritance Pattern

Susceptibility to familial cylindromatosis has an autosomal dominant pattern of inheritance, which means one copy of the altered gene in each cell increases the risk of developing this condition. However, a second, non-inherited mutation is required for development of skin appendage tumors in this disorder.

Other Names for This Condition

- Ancell-Spiegler cylindromas
- cylindromatosis, familial
- dermal eccrine cylindroma
- turban tumor syndrome

Diagnosis & Management

Genetic Testing Information

- What is genetic testing? /primer/testing/genetictesting
Research Studies from ClinicalTrials.gov

- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22dermal+eccrine+cylindroma%22+OR+%22Sweat+Gland+Neoplasms%22

Additional Information & Resources

Health Information from MedlinePlus

- Health Topic: Benign Tumors
  https://medlineplus.gov/benigntumors.html

- Health Topic: Skin Conditions
  https://medlineplus.gov/skinconditions.html

Genetic and Rare Diseases Information Center

- Dermal eccrine cylindroma
  https://rarediseases.info.nih.gov/diseases/10345/dermal-eccrine-cylindroma

Educational Resources

- American Cancer Society: Skin Cancer

- MalaCards: cylindromatosis, familial
  https://www.malacards.org/card/cylindromatosis_familial

Patient Support and Advocacy Resources

- AboutFace
  https://www.aboutface.ca/

- Skin Cancer Foundation
  https://www.skincancer.org/

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28familial+cylindromatosis %5BTIAB%5D%29+OR+%28ancell-spiegler+cylindromas%5BTIAB%5D%29+OR +%28turban+tumor+syndrome%5BTIAB%5D%29+OR+%28dermal+eccrine+cyli ndroma%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh %5D+AND+%22last+2160+days%22+AND+human%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- CYLINDROMATOSIS, FAMILIAL
  http://omim.org/entry/132700
Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17851586

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10835629

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15854031

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16272260
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1735949/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18008375

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18234730

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16922728


Reviewed: June 2012
Published: January 2, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services